A Safety, Pharmacokinetics, and Pharmacodynamics Study of ABX464 in HIV-1 Seronegative and Seropositive Adults
Status:
Completed
Trial end date:
2018-12-31
Target enrollment:
Participant gender:
Summary
The purpose of the ABX464-005 study is to characterize the systemic and mucosal immunological
sequelae associated with exposure to ABX464 and to explore selected immunological endpoints,
compartmental pharmacokinetics, and pharmacodynamics.